Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

HAPY Medical ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Bankruptcy risk for industry   1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0% 1.0%   Bankruptcy risk   8.5% 5.7% 6.5% 5.9% 6.4% 5.6% 16.7% 16.3%   Credit score (0-100)   30 40 35 39 36 41 10 11   Credit rating   BB BBB BBB BBB BBB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,862 2,461 3,310 4,992 4,679 4,498 0.0 0.0   EBITDA   540 738 1,405 2,767 2,615 2,568 0.0 0.0   EBIT   540 734 1,377 2,698 2,545 2,489 0.0 0.0   Pre-tax profit (PTP)   539.0 722.0 1,365.0 2,685.0 2,477.0 2,462.3 0.0 0.0   Net earnings   419.0 563.0 1,068.0 2,085.0 1,925.0 1,913.2 0.0 0.0   Pre-tax profit without non-rec. items   539 722 1,365 2,685 2,477 2,462 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Tangible assets total   0.0 37.0 175 106 36.0 281 0.0 0.0   Shareholders equity total   519 783 1,291 2,316 2,161 2,155 185 185   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,061 1,336 1,940 3,034 2,642 2,465 185 185   Net Debt   -392 -830 -1,128 -2,015 -2,240 -1,700 -185 -185     See the entire balance sheet 1000.0 Volume  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,862 2,461 3,310 4,992 4,679 4,498 0.0 0.0   Gross profit growth   65.4% 32.2% 34.5% 50.8% -6.3% -3.9% -100.0% 0.0%   Employees   2 2 2 2 2 2 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   1,061 1,336 1,940 3,034 2,642 2,465 185 185   Balance sheet change%   80.1% 25.9% 45.2% 56.4% -12.9% -6.7% -92.5% 0.0%   Added value   540.0 738.0 1,405.0 2,767.0 2,614.0 2,567.9 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 33 110 -138 -140 167 -281 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   29.0% 29.8% 41.6% 54.0% 54.4% 55.3% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   65.5% 61.2% 84.1% 108.5% 89.7% 97.5% 0.0% 0.0%   ROI %   145.4% 112.7% 132.8% 149.6% 113.7% 115.4% 0.0% 0.0%   ROE %   116.6% 86.5% 103.0% 115.6% 86.0% 88.7% 0.0% 0.0%   1000.0 Solidity  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Equity ratio %   48.9% 58.6% 66.5% 76.3% 81.8% 87.4% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -72.6% -112.5% -80.3% -72.8% -85.7% -66.2% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   8.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Quick Ratio   2.0 2.3 2.7 4.1 5.4 7.0 0.0 0.0   Current Ratio   2.0 2.3 2.7 4.1 5.4 7.0 0.0 0.0   Cash and cash equivalent   392.0 830.0 1,128.0 2,015.0 2,240.0 1,699.9 0.0 0.0   1000.0 Capital use efficiency  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   519.0 746.0 1,116.0 2,210.0 2,125.0 1,873.3 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024 2025/3 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   270 369 703 1,384 1,307 1,284 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   270 369 703 1,384 1,308 1,284 0 0   EBIT / employee   270 367 689 1,349 1,273 1,245 0 0   Net earnings / employee   210 282 534 1,043 963 957 0 0